top of page

IL-25-induced memory ILC2s mediate long-term small intestinal adaptation

18 maj 2025

Cortez et al. (BioRxiv) 

DOI: 10.1101/2025.03.25.645270

Keywords

  • Immunological memory

  • Innate lymphoid cells

  • Gut helminth infection

  • Small intestine adaptation

  • IL-25


Main Findings

Helminths have evolved complex  pathways to create favourable host environments. Through a  well-characterized immunoregulatory axis, helminths stimulate gut  epithelial tuft cells to produce IL-25, which activates group 2 innate  lymphoid cells (ILC2s). This drives epithelial proliferation and mucus  production, which prevent excessive damage to the intestinal barrier.  Prior studies have shown that epithelia can have ‘memory’ of previous  responses, marked by sustained transcriptional and epigenetic changes.  However, whether helminth-associated protective pathways can lead to  lasting immune memory in the gut remains unclear. In this preprint (not  peer-reviewed), Cortez et al. explore how IL-25 rewires mouse ILC2s to  promote durable host-protective adaptations.

The authors first confirmed that  intraperitoneal IL-25 injection induces small intestinal lengthening  and epithelial proliferation, which persisted for at least 50 days. At  the +50-day ‘memory’ time point, epithelial cells from IL-25-treated  mice had greater expression of IL-4 and IL-13 gene targets than  controls. Notably, ILC2s were more numerous in these mice and had  sustained IL-13 and IL-5 production. Rag2-/-IL2rg-/- mice, which lack all lymphocytes including ILCs, had no small intestine changes after IL-25 treatment, in contrast to Rag1-/-mice, which form ILCs. Furthermore, mice lacking IL-4 and IL-13, Il4ra (IL-4/IL-13 receptor), or Il17rb (IL-25 receptor) also had no intestinal changes in response to IL-25,  which shows the crucial role of type 2 cytokines produced by  IL-25-activated ILC2s. Importantly, IL-25 pretreatment protected rec  against secondary helminth infection.

Single-cell RNA sequencing and  bulk chromatin accessibility profiling suggested that ILC2s develop  memory-effector states after IL-25 exposure, characterized by marked  epigenetic alterations and increased expression of Il4, Il13 and Il5 as well as transcription factors such as Zeb2 and Maf.  Strikingly, exogenously administered IL-25 led to ILC2 and intestinal  adaptation without requiring endogenous IL-25, tuft cells or canonical  type 2 alarmins, indicating that IL-25 has a direct effect on ILC2s.  Further experiments ruled out impacts of epithelial stem cells or the  gut microbiota.

Conditional deletion of IL-25 receptor from IL-5-expressing cells or of all Il4ra+ cells after IL-25 treatment reduced epithelial adaptation. This  suggests the requirement for IL-25-responsive IL-5+ ILC2s and type 2  epithelial signalling in intestinal adaptation. Finally, transplanting  ILC2s from IL-25-conditioned mice into Rag2-/-IL2rg-/- mice protected against helminth challenge.

In summary, these findings lay a  strong foundation for elucidating how innate immune cells balance  tissue protection with mucosal pathogen defence by retaining ‘memory’ of  prior infection.


Limitations

Followup work could delve deeper  into transcriptomic and epigenomic landscapes to dissect  gene-regulatory networks underlying ILC2 memory. This includes further  characterising the roles of transcription factors like Zeb2, Hlf, Maf, and  others which are implicated in memory and effector states. The  single-cell transcriptomic data also revealed distinct ILC2  subpopulations, including those expressing Il17a or Gzma.  Further research will be needed to bioinformatically validate their  existence, and experimentally determine if all these populations  contribute to the memory state or if they have specialized roles.

Continued in vivo studies may explore why IL-25-activated ILC2s do not heighten gut  allergic sensitivity, and if memory ILC2s are truly independent of  alarmin signaling. Such exploration may help explain why activated ILC2s  do not fully recapitulate the same phenotypes when transferred into  naive hosts, or if other factors such as a longer required experiment  time frame are at play.

Finally, the majority of the  study utilizes intraperitoneal IL-25 injections to induce helminth-like  pathology in mice. While it is important to isolate the activation of  the tuft cell-ILC2 circuit from the wide immune effects of helminths, it  may be interesting to validate and further characterize the immune  memory of ILC2s in full parasite exposure.


Significance/Novelty

Cortez et al. advances our  understanding in the formation of innate immune memory in the context of  ILC2s and mucosal immunity. In particular, the study characterizes a  distinct form of memory ILC2 cells induced by IL-25 which are sustained  long-term and independent of alarmin or tuft cell signaling. This is  different from previously described epigenetically-mediated “trained  immunity” and IL-33-dependent ILC2 memory found in the lungs.  Furthermore, the tissue adaptation is present specifically in immune  ILC2 cells and not found in epithelial cells (where immunological memory  has been previously reported). Because activated ILC2s were found not  just in the gut but also at distal sites like the lung and adipose  tissue, the findings also suggest a pivotal role for ILC2s in mediating a  broad immune and mucosal barrier to helminth infection. As such, Cortez  et al. sets the groundwork for leveraging these non-specific responses  that are mediated by protective and tolerance pathways rather than  inflammatory mechanisms. Novel therapeutic strategies may attempt to  raise mucosal immunity without additional allergic sensitization or  chronic inflammation.


Credit

Reviewed by Brian Soong as part of a cross-institutional journal club between the Icahn School  of Medicine at Mount Sinai, the University of Oxford, the Karolinska  Institute and the University of Toronto.


The author declares no conflict of interests in relation to their involvement in the review.

bottom of page